title: Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: report of two cases with no evidence of systemic disease.
authors.forename: Ágota
authors.initials: Á
authors.lastname: Szepesi
authors.forename: Judit
authors.initials: J
authors.lastname: Csomor
authors.forename: Hajnalka
authors.initials: H
authors.lastname: Rajnai
authors.forename: Nóra
authors.initials: N
authors.lastname: Erős
authors.forename: Norbert
authors.initials: N
authors.lastname: Wikonkál
authors.forename: Sarolta
authors.initials: S
authors.lastname: Kárpáti
authors.forename: András
authors.initials: A
authors.lastname: Matolcsy
authors.forename: Márta
authors.initials: M
authors.lastname: Marschalkó
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone